Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Graves’ Eye Disease
source: American Thyroid Association (ATA)
year: N/A
summary/abstract:What is the Thyroid Gland?
The thyroid gland is a butterfly-shaped endocrine gland that is normally located in the lower front of the neck. The thyroid’s job is to make thyroid hormones, which are secreted into the blood and then carried to every tissue in the body. Thyroid hormone helps the body use energy, stay warm and keep the brain, heart, muscles, and other organs working as they should.
What is Graves Ophthalmopathy?
Graves’ eye disease, also called Graves’ ophthalmopathy or thyroid eye disease, is a problem that usually develops in people with an overactive thyroid caused by Graves’ disease (See brochure on Graves’ disease). Graves’ disease is an autoimmune disease caused by antibodies directed against receptors present in the thyroid cells and also on the surface of the cells behind the eyes. Rarely, it can also affect the skin, usually the front part of the legs. This usually results in a generalized over activity of the thyroid gland (hyperthyroidism). Up to one-half of people with Graves’ disease develop eye symptoms. These are usually mild and treatable.
read more
Related Content
-
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye DiseaseContext: Thyroid eye disease (TED), a v...
-
Enfermedad Ocular Tiroidea¿Qué es la Enfermedad Ocular Tiroidea?...
-
Steven Elliott Feldon, MD, MBASteven Elliott Feldon is an internationa...
-
Trial of Rituximab for Graves’ OphthalmopathyBrief Summary: This study is being done...
-
Does Early Response to Intravenous Glucocorticoids Predict the Final Outcome in Patients With Moderate-To-Severe and...Purpose: Intravenous glucocorticoids (i...
-
Review of the Literature and Report of a Large Series of Patients Regarding the Association of Other Autoimmune Dise...Several studies have reported an associa...
-
Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application...Horizon Therapeutics plc today announced...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.